Acetyl-L-carnitine (ALCAR) is an acetylated form of L-carnitine that crosses the blood-brain barrier more effectively than standard L-carnitine. It has been studied for cognitive decline, Alzheimer's disease, peripheral neuropathy, depression, blood pressure, cardiovascular health, insulin resistance, and male infertility. This article synthesizes clinical trial data from meta-analyses, Cochrane Reviews, and randomized controlled trials — covering every major study on ALCAR with sample sizes, dosages, durations, and effect sizes.
Table of Contents
- Overview
- Forms and Bioavailability
- Evidence for Benefits
- Recommended Dosing
- Dietary Sources
- Safety and Side Effects
- Drug Interactions
- References
Overview
Acetyl-L-carnitine (ALCAR) is an acetylated form of L-carnitine, a naturally occurring compound derived from the amino acids lysine and methionine [1][2]. Carnitine plays a critical role in energy production by transporting long-chain fatty acids into the mitochondria, where they undergo beta-oxidation to produce adenosine triphosphate (ATP) [1][3]. Approximately 95% of total body carnitine is stored in heart and skeletal muscle, with the remainder in the liver, kidneys, and circulating plasma [1][4].
What distinguishes acetyl-L-carnitine from standard L-carnitine is the acetyl group attached at the 3-position oxygen, which increases lipophilicity and allows ALCAR to cross the blood-brain barrier more effectively than L-carnitine [5][6]. This property enables ALCAR to influence central nervous system functions, including neurotransmitter synthesis, mitochondrial energy metabolism in neurons, and neuroprotection [2][5]. ALCAR is believed to play a role in the production of acetylcholine, an important neurotransmitter involved in memory and learning, by donating acetyl groups to choline [7][8].
The body synthesizes carnitine endogenously in the liver, kidneys, and brain. Healthy adults produce approximately 14.4 mg/day, which, combined with dietary intake, is sufficient to meet carnitine needs under normal conditions [1][4]. The Food and Nutrition Board of the National Academies concluded in 1989 that carnitine is not an essential nutrient and did not establish Dietary Reference Intakes (DRIs) [1][9]. However, carnitine becomes conditionally essential under certain conditions, such as premature birth, end-stage renal disease, or genetic transport defects [1][2].
Dietary carnitine has a bioavailability of approximately 63–75% from foods [1][10]. In contrast, absorption of supplemental L-carnitine is substantially lower at 14–18% [1][10]. Unabsorbed carnitine is degraded by microorganisms in the large intestine [11]. The bioavailability of supplemental acetyl-L-carnitine has not been as well studied, though some evidence suggests slightly higher circulating concentrations compared to equivalent L-carnitine doses, with peak plasma levels typically achieved 2–4 hours after oral administration [5][12].
Carnitine status can be assessed by measuring circulating carnitine levels. A plasma free carnitine concentration of 20 mcmol/L or less, or a total carnitine concentration of 30 mcmol/L or less, is considered abnormally low [1]. The ratio of acyl-L-carnitine ester to free L-carnitine (a ratio of 0.4 or greater indicates abnormal metabolism) can also be used [1].
ALCAR has been approved in various countries for indications including cerebrovascular disorders, mental function enhancement, and nutritional supplementation [5]. It is widely available as an over-the-counter dietary supplement, with the global market valued at $58.1 million in 2023, projected to grow to $97.5 million by 2033 [5].
Forms and Bioavailability
Carnitine Forms Comparison
Several forms of carnitine are used in supplements and clinical settings. Each has distinct properties and applications. It is important not to substitute one form for another, as the benefits of each form may depend on the intact molecule or its specific metabolites [11].
| Form | Key Properties | Primary Uses |
|---|---|---|
| Acetyl-L-Carnitine (ALCAR) | Acetylated form. Crosses blood-brain barrier. Molecular formula C₉H₁₇NO₄ (MW 203.24 g/mol). Oral bioavailability higher than L-carnitine supplements [5][12]. | Cognitive decline, neuropathy, depression, blood pressure [2][5][7] |
| L-Carnitine | Unacetylated form. Oral supplement bioavailability 14–18%. Dietary bioavailability 63–75% [1][10]. | Cardiovascular disease, athletic performance, weight loss, dialysis-related deficiency [1][3] |
| Propionyl-L-Carnitine | Acyl derivative of L-carnitine. | Peripheral artery disease, intermittent claudication, sexual dysfunction [3][13] |
| L-Carnitine-L-Tartrate | Combined with tartaric acid. NOT found to be more bioavailable than L-carnitine in a study of 5 healthy men [11]. | Exercise recovery (marketed, limited evidence) |
| L-Carnitine Fumarate | Combined with fumaric acid. Lower absorption than L-carnitine [14]. | Generally not recommended due to inferior absorption |
| D-Carnitine | Biologically inactive stereoisomer. Should NOT be used — competes with active L-forms and can cause symptoms of carnitine deficiency [11]. | None (contraindicated) |
Bioavailability and Absorption
ALCAR is absorbed primarily through the gastrointestinal tract via a combination of active transport and passive diffusion [5][12]. Its acetylated structure enhances absorption compared to L-carnitine supplements, with studies demonstrating a 43% increase in circulating ALCAR concentrations following daily oral doses of 2 g [12]. Peak plasma levels are typically achieved 2–4 hours after oral administration [5][12].
Transport of ALCAR across cell membranes, including the blood-brain barrier, is primarily mediated by the organic cation/carnitine transporter 2 (OCTN2, encoded by SLC22A5), a sodium-dependent transporter expressed on the luminal side of endothelial cells [5]. This transporter exhibits high affinity for ALCAR, enabling efficient delivery to neuronal cells.
ALCAR is eliminated mainly through renal excretion, with the unchanged compound and its metabolites (such as L-carnitine following deacetylation) appearing in urine. Renal reabsorption is efficient at low plasma concentrations but becomes saturated at higher levels, leading to increased clearance. Plasma concentrations return to baseline within 12 hours after intravenous administration of 0.5 g [5][12].
Chemical Stability
Acetyl-L-carnitine is stable in neutral to acidic aqueous solutions (pH below 9) but degrades rapidly at alkaline pH values greater than 9, with significant loss of integrity observed after short exposure times at room temperature [5]. This pH-dependent stability influences handling in pharmaceutical preparations, where acidic or neutral conditions are preferred.
The hydrochloride salt (C₉H₁₈ClNO₄) is the most common commercial form, appearing as a white to off-white crystalline powder with a melting point of approximately 194°C. It exhibits high solubility in water (greater than 100 mg/mL) and ethanol (approximately 20 mg/mL) [5].
Evidence for Benefits
Memory and Cognitive Function
Alzheimer's Disease and Dementia
ALCAR has been one of the most extensively studied dietary supplement ingredients for memory disorders. Its mechanism involves supporting acetylcholine synthesis and helping remove toxic compounds to alleviate mitochondrial dysfunction associated with degeneration of brain structures [2][15].
Montgomery et al. 2003 meta-analysis: A meta-analysis of 21 clinical trials including a total of 1,204 adults with mild cognitive impairment or mild Alzheimer's disease examined the effects of 1.5 to 3.0 g/day acetyl-L-carnitine versus placebo for 3 to 12 months. Clinical and psychometric assessment scores were better, and clinician-determined improvements were greater in supplement users than in placebo groups [16].
Hudson & Tabet 2003 Cochrane Review: A Cochrane Review of 15 clinical trials (including 13 of those in the meta-analysis above) assessed 1 to 3 g/day ALCAR supplementation versus placebo over 12 to 52 weeks in participants with mild to moderate dementia or cognitive decline. The results showed that supplementation decreased symptom severity at 12 and 24 weeks but NOT at 52 weeks. Similarly, ALCAR improved Mini Mental State Examination (MMSE) scores at 24 weeks but not at 12 or 52 weeks. It had no effect on the severity of dementia, functional ability, or overall clinical global impression scores. The authors noted that results from more recent studies were less positive than those from earlier studies, and concluded that routine clinical use of ALCAR to treat dementia signs and symptoms was not justified [15].
Spagnoli et al. 1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17].
Thal et al. 1996 (multicenter trial): A larger multicenter, randomized, double-blind, placebo-controlled study enrolled 431 patients with mild to moderate probable Alzheimer's disease, administering 3 g/day of ALCAR for 12 months. While overall decline rates were similar between groups, post-hoc subgroup analysis indicated slower cognitive decline in early-onset patients (aged 65 or younger) compared to placebo, as measured by the Alzheimer's Disease Assessment Scale cognitive subscale and Clinical Dementia Rating Scale [5][18].
Summary: While early studies found evidence of modest benefit, later and larger studies failed to find ALCAR effective for established dementia [15]. If there is any benefit at all, it may be limited to people with mild cognitive impairment and early Alzheimer's disease, and particularly to younger-onset cases [7][16]. The effects remain an area of active research [2][19][20].
Preclinical Combination Data (ALCAR + Alpha-Lipoic Acid)
Preclinical studies in aged rats have demonstrated that combining ALCAR with alpha-lipoic acid (ALA) synergistically improves cognitive function more effectively than either compound alone. Dietary supplementation restored performance on spatial memory (Morris water maze) and temporal memory tasks, reduced oxidative damage to RNA in the hippocampus, and reversed age-associated mitochondrial structural decay (fewer broken cristae, more intact mitochondria). Similar trends were observed in ApoE4 mouse models relevant to Alzheimer's risk. While direct human trials on the combination for cognition are sparse, the mechanistic synergy — ALCAR supporting fatty acid transport and acetylcholine synthesis, ALA providing broad antioxidant protection — supports potential for addressing mitochondrial dysfunction in age-related cognitive decline [5].
Blood Pressure
Acetyl-L-carnitine (500 to 1,000 mg taken twice daily) for a period of months may modestly reduce systolic blood pressure in people with high blood pressure, although it does not appear to lower diastolic blood pressure [7].
Ruggenenti et al. 2009: A study found that taking 1 gram of acetyl-L-carnitine twice daily for 6 months lowered systolic blood pressure by approximately 8 mmHg compared to baseline. However, this study did not include a comparison group, making the results uncertain [7][21].
McMackin et al. 2007: A study in 36 people (average age 63) with coronary artery disease found that taking 500 mg of acetyl-L-carnitine plus 200 mg of alpha-lipoic acid twice daily for 8 weeks lowered systolic blood pressure by 9 mmHg in those with coronary artery disease and high blood pressure, which was significant compared to placebo. The study was partially funded by the maker of the supplement (Juvenon Cellular Health Supplement, Juvenon Inc.) [7][22].
Parvanova et al. 2018 (DIABASI trial): A study in 219 older people with high blood pressure, high cholesterol, and diabetes found that taking 1 gram of acetyl-L-carnitine twice daily for 6 months did NOT lower systolic blood pressure compared to placebo. The participants were taking the cholesterol-lowering medicine simvastatin, which can also lower blood pressure and may have overshadowed any effects of acetyl-L-carnitine [7][23]. This trial also observed no significant changes in glycemic control or insulin sensitivity [5].
Insulin sensitivity pilot study (Ruggenenti): A pilot study in nondiabetic subjects at increased cardiovascular risk with insulin resistance found that 2 g/day of oral ALCAR for 6 months improved insulin-mediated glucose disposal (measured by euglycemic hyperinsulinemic clamp) alongside reductions in blood pressure [5][21].
Peripheral Neuropathy
Diabetic Neuropathy
Guidelines from the American Society of Pain and Neuroscience (ASPN) state that, although dietary supplements including acetyl-L-carnitine may have a role in managing painful diabetic neuropathy, there is insufficient high-quality evidence comparing ALCAR to typical pharmacologic drugs, and there is not enough information about safe dosing, to recommend for or against its use [7][24].
Li et al. 2019 meta-analysis: A systematic review and meta-analysis of four randomized controlled trials involving patients with painful peripheral neuropathy found that ALCAR significantly reduced pain by 20.2% (95% CI: 8.3–32.1%, P < 0.0001) relative to baseline on a 10-cm Visual Analog Scale. A subgroup of three RCTs in diabetic peripheral neuropathy showed even greater relief at 24.6% (95% CI: 12.4–36.8%, P < 0.0001). Evidence was graded as Class II (probably effective) per American Academy of Neurology guidelines [5][25].
2019 Cochrane Review: A Cochrane review of RCTs on ALCAR for diabetic peripheral neuropathy concluded very low-certainty evidence (GRADE system) indicating uncertainty regarding short-term pain relief, but noted potential improvements in nerve conduction velocity. It highlighted gaps in long-term data beyond 6–12 months and heterogeneity in dosing protocols [5][26].
Clinical evidence demonstrates that oral doses of 1–3 grams per day, administered for 6–12 months, can reduce neuropathic pain scores, with enhancements in nerve fiber regeneration and sensory function, particularly when combined with standard therapies [5]. Dosing regimens typically start at 500 mg twice daily, titrated up to 1.5–3 grams per day. Intravenous administration is sometimes used initially for severe cases to achieve faster symptom relief [5].
Antiretroviral-Associated Neuropathy
Youle et al. 2007: A small, multicenter clinical study among 56 people with neuropathy associated with antiretroviral drug therapy showed that receiving 500 mg of acetyl-L-carnitine twice daily intramuscularly for two weeks, followed by 1,000 mg twice daily orally for 6 weeks, reduced pain by 0.89 points (on a 0–10 scale) compared to placebo. However, it did not reduce pain, burning, or numbness based on two other symptom scales [7][27].
Chemotherapy-Induced Neuropathy — CAUTION
Hershman et al. 2018: A double-blind, placebo-controlled study among women receiving taxane-based chemotherapy to treat breast cancer found that 3 grams of acetyl-L-carnitine taken daily for 5.5 months significantly WORSENED symptoms of chemotherapy-induced peripheral neuropathy compared to placebo, and this difference persisted after 2 years. The effect was unexpected, although a similar problem has been observed with other antioxidants given during chemotherapy [7][28].
Loprinzi et al. 2020 (ASCO guideline): Based on the above evidence, the American Society of Clinical Oncology recommended in 2020 that clinicians DISCOURAGE use of acetyl-L-carnitine for preventing chemotherapy-related nerve damage [29].
Depression
ALCAR shows promise in treating depression, with research dating back to the 1990s highlighting antidepressant-like effects through modulation of neurotransmitter systems [5].
Veronese et al. 2017 meta-analysis: A systematic review and meta-analysis of nine randomized controlled trials showed that ALCAR supplementation significantly decreased depressive symptoms compared to placebo (standardized mean difference −1.10, 95% CI −1.65 to −0.56), with effects comparable to established antidepressants like fluoxetine, particularly in older adults or those with treatment-resistant depression [5][30].
Early studies from the late 1990s reported that supplementation at 1–2 grams per day improved mood and reduced fatigue in patients with major depressive disorder, as evidenced by reductions in Hamilton Depression Rating Scale scores by about 20–30% over 4–8 weeks [5].
Fibromyalgia
Leombruni et al. 2015: A study of 51 people with fibromyalgia (average age 52) compared 500 mg of acetyl-L-carnitine three times daily versus 30 to 60 mg of duloxetine (an antidepressant) daily. Those given ALCAR did NOT experience an improvement in pain intensity or anxiety compared to baseline. While they showed a 2.18-point improvement (on a 7-point scale) in overall severity of illness and a reduction in depression based on one scale, they did not show improvement in depression based on another scale. Those in the duloxetine group showed similar improvements in depression and no improvement in anxiety, but DID show reduction in pain compared to baseline. Critically, the study lacked a placebo group, making it impossible to determine whether ALCAR was truly beneficial [7][31].
Chronic Fatigue Syndrome
A 2004 randomized trial demonstrated decreased fatigue severity and improved quality of life metrics in patients with chronic fatigue syndrome after 24 weeks of treatment at 2 grams daily [5][32].
Cardiovascular Disease
Carnitine plays a role in transporting long-chain fatty acids in the myocardial mitochondria for energy production, moderating oxidative stress, and potentially decreasing markers of inflammation. During ischemic events, carnitine prevents fatty acid ester accumulation, which can lead to fatal ventricular arrhythmias [3][33][34].
Acute Myocardial Infarction — DiNicolantonio et al. 2013 meta-analysis: A meta-analysis of 13 clinical trials including 3,629 adults with acute myocardial infarction who took L-carnitine (from 2.7 g/day for 5 days to 6 g/day for 12 months) versus placebo found that L-carnitine significantly reduced rates of all-cause mortality, ventricular arrhythmias, and new-onset angina. However, it did not affect risk of heart failure or myocardial reinfarction. The carnitine dose and duration did not appear to affect outcomes [3][33].
Chronic Heart Failure — Song et al. 2017 meta-analysis: A meta-analysis of 17 clinical trials including 1,625 adults with chronic heart failure found that 1–6 g/day L-carnitine supplements for 7 days to 3 years improved left ventricular ejection fraction by 4.14%, stroke volume by 8.21 mL, and cardiac output by 0.88 L/min compared to routine/conventional treatment. These benefits did not vary by supplement dose or study duration. However, L-carnitine did not affect rates of all-cause mortality or performance on a timed walking test [3][35].
TMAO and Cardiovascular Risk — Important Concern: Koeth et al. (2013, Nature Medicine) found that L-carnitine is metabolized by intestinal microbiota to trimethylamine-N-oxide (TMAO), a proatherogenic substance associated with increased CVD risk. In 2,595 adults aged 54–71, omnivorous participants produced more TMAO than vegans or vegetarians after L-carnitine consumption. Dose-dependent associations existed between L-carnitine levels and risk of coronary artery disease, peripheral artery disease, and CVD — but only in participants with concurrently high TMAO levels [3][7][36]. Although ALCAR is not identical to L-carnitine, it contains the same TMA moiety and may potentially foster TMAO-producing organisms [7][36].
Johri et al. 2022 (atherosclerosis RCT): A clinical trial in 157 individuals aged 58–75 with metabolic syndrome who received 1 g L-carnitine or placebo twice daily for 6 months found that total cholesterol and LDL cholesterol levels were higher in participants taking L-carnitine. L-carnitine supplementation was also associated with 9.3% greater carotid arterial plaque stenosis in males who ate less red meat [3][37].
Peripheral Artery Disease — Tama et al. 2021: A systematic review of three RCTs compared 234 participants taking 2 g/day oral propionyl-L-carnitine for 4–6 months with 222 patients on placebo. One trial showed improved peak walking times and decreased pain; the other two showed no benefit [3][38].
Insulin Resistance and Diabetes
Insulin resistance may be associated with mitochondrial dysfunction and defects in fatty-acid oxidation in muscle. Carnitine supplementation has therefore been studied for possible effects on insulin resistance and diabetes [3][39][40].
Zamani et al. 2023 meta-analysis: A meta-analysis of 41 randomized clinical trials examined the effects of L-carnitine supplementation on glycemic markers in 2,900 men and women aged 18 years and older. Most participants had health conditions such as type 2 diabetes, obesity, polycystic ovary syndrome, or nonalcoholic fatty liver disease. L-carnitine supplements at doses of 0.25 to 4 g/day for 2 to 52 weeks reduced fasting blood glucose, insulin resistance, and glycosylated hemoglobin (HbA1c) but NOT serum insulin levels [3][41].
Xu et al. 2017 meta-analysis: A meta-analysis of five randomized clinical trials in 631 adults with insulin resistance who took 2 or 3 g/day L-carnitine or placebo for 4 weeks to 12 months found that L-carnitine improved measures of insulin resistance. Benefits at 12 months exceeded those at 3 months [3][42].
Vidal-Casariego 2013 meta-analysis: A systematic review and meta-analysis of four randomized clinical trials with 284 adults with type 2 diabetes compared L-carnitine with placebo. The results showed that 2 or 3 g/day L-carnitine for 12 to 52 weeks reduced levels of fasting plasma glucose, total cholesterol, LDL cholesterol, and apolipoproteins B100 and A1 but NOT triglycerides, lipoprotein(a), or HbA1c [3][43].
Male Infertility
Carnitine plays a role in sperm maturation, motility, and spermatogenesis, and may reduce oxidative stress that could improve oocyte growth and maturation [3][44][45].
Salas-Huetos et al. 2018 meta-analysis: A systematic review and meta-analysis of three randomized clinical trials examining 1–3 g/day L-carnitine or acetyl-L-carnitine for 2 to 6 months on sperm parameters in 201 men aged 20–40 years with infertility found that supplemental carnitine improved sperm motility by 7.84% and morphology by 4.91% but did NOT affect sperm concentration [3][46].
de Ligny et al. 2022 Cochrane Review: A review of six randomized clinical trials in 1,089 men with subfertility who took 1,000–3,000 mg/day carnitine for 8 weeks to 6 months found that carnitine supplementation increased sperm motility and concentration at some timepoints (e.g., 3 months) but did NOT affect rates of live birth or pregnancy [3][47].
Mongioi et al. 2020 meta-analysis: A systematic review confirmed that supplementation with L-carnitine and acetyl-L-carnitine significantly improved total sperm motility, progressive sperm motility, and sperm morphology in men with idiopathic infertility, but did not significantly affect sperm concentration or clinical pregnancy rates. Research indicates that combined supplementation at doses of at least 3 g per day is required for significant effects [5][48].
Female Infertility (PCOS)
Ismail et al. 2014: A 26-month randomized controlled trial of 170 women younger than 35 with PCOS found that those taking clomiphene citrate plus 3 g/day supplemental L-carnitine (from day 3 of their menstrual cycle until the day of their first positive pregnancy test) had 64.4% higher ovulation rates and thicker endometrial tissue (10.1 mm vs. 6.8 mm) than the placebo group. More participants in the L-carnitine group became pregnant and had fewer miscarriages [3][49].
El Sharkwy et al. 2019: A 3-month randomized controlled trial of 280 women with PCOS found that those receiving 3 g L-carnitine had improved menstrual cycle regularity and higher ovulation and pregnancy rates, but miscarriage rates did not differ between groups [3][50].
Osteoarthritis
Mahdavi et al. 2016: A randomized clinical trial in 69 women aged 40–60 with mild to moderate knee osteoarthritis found that 250 mg L-carnitine three times daily for 8 weeks reduced several inflammation biomarkers and pain scores compared to placebo: interleukin-1-beta levels decreased 5.53%, matrix metalloproteinase-1 levels decreased 9.10%, and the visual analog scale of pain decreased 52.67% [3][51].
Baghban et al. 2021: A randomized clinical trial of 76 women (average age 55) with obesity and knee osteoarthritis found that 1 g/day L-carnitine for 12 weeks did NOT reduce osteoarthritis pain or stiffness or increase physical function compared to placebo [3][52].
Leg Cramps
High doses of L-carnitine given orally (typically 1,500 mg or more per day) or intravenously have been used to treat leg cramps and nocturnal leg cramps due to carnitine deficiency, which can occur due to genetic disorders (primary carnitine deficiency), medical conditions such as liver cirrhosis and chronic kidney failure, or use of certain medications [7][53][54].
Miwa 2020: L-carnitine supplementation (1,500 mg per day for one week, then reduced to 750 mg per day thereafter) has been reported to reduce the frequency of nocturnal leg cramps after stroke [7][55].
Imbe et al. 2018: L-carnitine at 600 mg per day reduced leg cramps among people with type 1 and type 2 diabetes [7][56].
However, there do not appear to be any published clinical trials specifically on acetyl-L-carnitine (as opposed to L-carnitine) in people with leg cramps or nocturnal leg cramps [7].
Athletic Performance
Carnitine helps preserve muscle glycogen and promotes fat oxidation, spares amino acid use as energy sources during exercise (making them available for new protein synthesis), and decreases lactate accumulation [3][57]. However, findings on supplemental carnitine for athletic performance are mixed.
Wall et al. 2011: A study randomly assigned 14 recreational athletes aged 24–28 to consume a carbohydrate solution with or without 2.0 g L-carnitine tartrate twice daily for 24 weeks. At the end of the trial, perceived exertion on a cycle ergometer at 50% and 80% VO₂max was lower in the carnitine group (14.0, Borg scale) than the control group (16.2) [3][58].
Novakova et al. 2016: In 24 men aged 18–40 (eight omnivores and 16 vegetarians) taking 1 g L-carnitine twice daily for 12 weeks, carnitine supplementation had no significant effect on VO₂max, blood lactate concentration, skeletal muscle energy metabolism, or physical performance in either vegetarians or omnivores. However, carnitine supplementation increased skeletal muscle carnitine stores in vegetarians (but not omnivores) by approximately 13% [3][59].
Fielding et al. 2018 (comprehensive review): A review summarizing effects of supplemental L-carnitine on exercise performance in well-trained athletes (aged 16–36) and recreationally active adults (aged 18–50) included 11 clinical trials in 251 well-trained athletes who took 1–4 g L-carnitine or placebo up to 6 months. L-carnitine reduced lactate levels and heart rate, increased lipid metabolism, VO₂max, and oxygen consumption, improved performance, and hastened recovery in SOME studies but not others. In 17 studies including 237 recreationally active adults, results were similarly mixed [3][60].
Mielgo-Ayuso et al. 2021 systematic review: A systematic review of 11 randomized clinical trials in 203 physically active and untrained adults aged 18–46 found mixed results. Some studies found significant improvements in VO₂max, peak power, perceived exertion, and repetitions in leg press; others found no differences. No studies found that L-carnitine improved moderate-intensity exercise performance [3][61].
Weight Loss
Villani et al. 2000: A study in which moderately obese women were given 2 grams daily of L-carnitine for eight weeks showed no effect on body fat or body weight [7][62].
Pooyandjoo et al. 2016 meta-analysis: A systematic review and meta-analysis combining results from nine randomized clinical trials in 911 participants found that study participants taking carnitine supplements lost an average of 1.33 kg more weight than those who took placebo, regardless of study duration or L-carnitine dose [3][63].
Derosa et al. 2010: In 258 adults aged 47–59 with uncontrolled type 2 diabetes, participants taking 2 g/day L-carnitine plus orlistat (360 mg/day) for 1 year lost more weight (11.3 kg) than those taking orlistat alone (9.5 kg) [3][64].
Derosa et al. 2003: 2 g/day L-carnitine alone for 6 months did NOT affect weight loss in 94 overweight men and women with newly diagnosed type 2 diabetes [3][65].
Androgen Decline in Older Men
Taking acetyl-L-carnitine in combination with propionyl-L-carnitine appears to help symptoms of androgen decline in older men, improving sexual dysfunction, depression, and fatigue. For symptoms of age-related testosterone deficiency, 2 grams of acetyl-L-carnitine plus 2 grams of propionyl-L-carnitine daily have been used [7][11].
Peyronie's Disease
Acetyl-L-carnitine may be helpful in Peyronie's disease (an inflammatory condition of the penis), where it has been shown to reduce pain and slow progression of the disease. A dose of 2 grams divided into two doses daily for 3 months has been studied (Biagiotti 2001) [7][66].
Eye Health
Clinical observations from combination therapies including acetyl-L-carnitine, omega-3 fatty acids, and coenzyme Q10 have reported significant reductions in irritation symptoms, clinical signs, and the need for topical treatments for dry eye syndrome after three months of use [5][67].
Sarcopenia
Preliminary evidence suggests acetyl-L-carnitine may help preserve muscle mass and function in the elderly by improving mitochondrial efficiency and reducing fatigue. Supplementation has been associated with increased muscle strength, mobility, and overall physical well-being in geriatric populations [5][68].
Fragile X Syndrome
Early research suggests that acetyl-L-carnitine might reduce hyperactivity in boys with fragile X syndrome. The daily dose studied was 20 to 50 mg/kg [7][11].
Hemodialysis and Renal Disease
Individuals with end-stage renal disease, particularly those on hemodialysis, often become carnitine insufficient due to reduced synthesis and increased elimination by the kidneys. Low carnitine levels can contribute to anemia, muscle weakness, fatigue, altered blood fats, and heart disorders [1][3].
Hurot et al. 2002 meta-analysis: A meta-analysis of studies in hemodialysis patients found that high doses of supplemental carnitine (often injected) might help manage anemia but not blood-lipid profiles. Effects on exercise capacity and heart disorders were inconclusive. Most studies were small and not double-blind [3][69].
Recommended Dosing
There is no established Dietary Reference Intake for carnitine. The following dosing ranges are based on clinical trial protocols:
| Indication | Dose (Acetyl-L-Carnitine) | Duration |
|---|---|---|
| Alzheimer's disease / dementia | 1.5–4 g/day, divided into 2–3 doses | 3–12 months [7][11] |
| Age-related memory impairment | 1.5–2 g/day | Ongoing [7][11] |
| Depression in elderly | 1.5–3 g/day, divided doses | 4–12 weeks [5][7][11] |
| Blood pressure | 1–2 g/day (500–1,000 mg twice daily) | 2–6 months [7][21][22] |
| Diabetic neuropathy | 1.5–3 g/day, divided doses (higher dose may be more effective for vibratory sensation and pain) | 6–12 months [5][7][11] |
| Antiretroviral neuropathy | 1 g twice daily | 6–8 weeks [7][27] |
| Fibromyalgia | 1.5 g/day (500 mg three times daily) | Variable [7][31] |
| Male infertility | 3–4 g/day (sometimes as mixed ALCAR + L-carnitine) | 2–6 months [7][11] |
| Peyronie's disease | 2 g/day, divided into 2 doses | 3 months [7][66] |
| Androgen decline (older men) | 2 g ALCAR + 2 g propionyl-L-carnitine daily | Variable [7][11] |
| Fragile X syndrome (children) | 20–50 mg/kg/day | Variable [7][11] |
| Chronic fatigue syndrome | 2 g/day | 24 weeks [5][32] |
| Insulin resistance / diabetes | 2–3 g/day (L-carnitine) | 4 weeks to 12 months [3][41][42] |
Acetyl-L-carnitine is taken in fairly large doses — often measured in grams rather than milligrams (1,000 mg = 1 gram). Doses are typically divided into two or three administrations per day.
For general cognitive support, doses of 1–2 g/day are common. For neuropathic conditions, higher doses of 2–3 g/day are typically used. Doses of approximately 3 g/day or more are associated with increased gastrointestinal side effects [1][11].
Dietary Sources
Carnitine is found primarily in animal products, especially red meat [1][10]. An omnivorous diet provides approximately 24–145 mg carnitine daily, while a vegan diet provides only about 1.2 mg [1]. The body needs approximately 15 mg/day from a combination of dietary sources and endogenous synthesis [1].
| Food | Serving | Carnitine (mg) |
|---|---|---|
| Beef steak, cooked | 3 ounces | 42–122 |
| Ground beef, cooked | 3 ounces | 65–74 |
| Milk, whole | 1 cup | 8 |
| Codfish, cooked | 3 ounces | 3–5 |
| Chicken breast, cooked | 3 ounces | 2–4 |
| Ice cream | ½ cup | 3 |
| Cheese, cheddar | 2 ounces | 2 |
| Whole-wheat bread | 2 slices | 0.2 |
| Asparagus, cooked | ½ cup | 0.1 |
Source: NIH Office of Dietary Supplements [1]. Poultry, fish, and dairy provide some carnitine, while vegetables, fruits, and grains provide negligible amounts. Endogenous synthesis in the liver and kidneys, combined with dietary intake, is sufficient for healthy individuals [1][4]. A person weighing 165 lb on a strict vegetarian diet synthesizes approximately 14.4 mg/day of carnitine endogenously [1].
Safety and Side Effects
General Safety Profile
Acetyl-L-carnitine is generally considered safe and well-tolerated at recommended doses [5][7]. Carnitine does not have an established tolerable upper intake level [1].
Common Side Effects
- Gastrointestinal: Nausea, vomiting, abdominal cramps, and diarrhea — the most common adverse effects, occurring primarily at doses exceeding 3 g/day [1][5][7].
- Fishy body odor: Carnitine supplementation at approximately 3 g/day can cause urine, breath, and sweat to have a fishy odor [1][7].
- Agitation and restlessness: ALCAR may cause agitation in some users. Mild nervous system effects including restlessness and insomnia have been reported, particularly when taken in elevated doses or later in the day [5][7].
- Muscle weakness: Can occur in people with uremia [1].
- Seizures: Can potentially increase the number or severity of seizures in those with seizure disorders [1][5].
Populations Requiring Caution
Thyroid disorders: People with low or borderline-low thyroid levels should NOT take acetyl-L-carnitine or other forms of carnitine because it may impair thyroid hormone function. Low thyroid levels are particularly common among women over 60 years of age. Conversely, in cases of hyperthyroidism, giving carnitine may be helpful [7][70].
Chemotherapy patients: ALCAR significantly worsened chemotherapy-induced peripheral neuropathy in a placebo-controlled trial (Hershman et al. 2018). The American Society of Clinical Oncology recommends AGAINST use for preventing chemotherapy-related nerve damage [28][29].
Seizure disorders: Individuals with a history of seizure disorders should exercise caution, as ALCAR has been associated with increased number or severity of seizures in some cases, particularly at high doses [1][5].
Renal disease / dialysis: Individuals on dialysis should not take carnitine without physician supervision [7]. Renal diseases can impair carnitine homeostasis due to reduced synthesis and increased elimination [1][3].
Pregnancy and breastfeeding: Insufficient evidence exists to establish safety during pregnancy and breastfeeding.
TMAO Cardiovascular Concern
Some research suggests that L-carnitine intake may contribute to cardiovascular disease in certain people. People who eat red meat maintain organisms in their gut that digest carnitine to trimethylamine (TMA), a precursor to TMAO, which appears to advance atherosclerosis by reducing normal cholesterol clearing [7][36]. Vegetarians and vegans do not have this reaction when first exposed to carnitine. Supplementing with carnitine (including acetyl-L-carnitine due to their chemical similarity — both contain the TMA moiety) may potentially foster growth of these organisms, increase TMAO levels, and have negative long-term cardiovascular effects, although clinical evidence is mixed [7][36][37].
Hair Loss Concerns
No robust scientific evidence links ALCAR supplementation to hair loss. Studies on related carnitine forms, such as L-carnitine-L-tartrate, actually indicate potential promotion of scalp hair growth through upregulation of proliferation and downregulation of apoptosis in follicular cells. Anecdotal reports of hair loss among users are often attributable to confounding factors such as stress, dietary deficiencies, or unrelated medications [5].
Drug Interactions
Blood Thinners (Anticoagulants)
ALCAR should be used with caution in people taking blood-thinning medication, as it can theoretically increase the anticoagulant effect, increasing the risk of bruising and bleeding. Regular INR monitoring is recommended when co-administered with warfarin [7][5].
Thyroid Medications
ALCAR may decrease the effectiveness of thyroid hormone by interfering with its activity, potentially necessitating monitoring or dosage adjustments in patients on levothyroxine or similar therapies [5][7][70].
Anticonvulsants (Valproic Acid)
Treatment with the anticonvulsants valproic acid, phenobarbital, phenytoin, and carbamazepine reduces blood levels of carnitine [1][71][72][73]. Valproic acid with or without other anticonvulsants may cause hepatotoxicity and increase plasma ammonia concentrations, leading to encephalopathy. Intravenous L-carnitine administration may help treat valproic acid toxicity, although the optimal regimen has not been identified [1][74][75].
Pivalate-Conjugated Antibiotics
Carnitine interacts with pivalate-conjugated antibiotics such as pivampicillin (used to prevent urinary tract infections). Chronic administration can lead to carnitine depletion, though no cases of illness due to carnitine deficiency in this population have been described [1][10][76].
Famotidine (H2 Blockers)
Sato et al. 2025: A retrospective study among 25 adults (average age 23) requiring carnitine replacement therapy showed that those on famotidine (found in Pepcid and Zantac 360) were much more likely to have low carnitine levels despite L-carnitine supplementation compared to those not taking famotidine (36.8% vs. 3.9%). Famotidine can increase urinary carnitine excretion by inhibiting a kidney transporter that helps retain carnitine. It may be prudent for people at risk for carnitine deficiency to avoid famotidine [7][77].
References
1. National Institutes of Health, Office of Dietary Supplements. "Carnitine — Health Professional Fact Sheet." https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/
2. Ferreira GC, McKenna MC. "L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain." Neurochem Res 2017;42:1661-75. https://pubmed.ncbi.nlm.nih.gov/28508995/
3. National Institutes of Health, Office of Dietary Supplements. "Carnitine — Health Professional Fact Sheet." (Carnitine and Health sections). https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/
4. Borum PR. "Carnitine." In: Marriott B, Birt DF, Stalling V, Yates A, eds. Present Knowledge in Nutrition, 11th ed. 2020:551-9.
5. Grokipedia. "Acetyl-L-carnitine." https://grokipedia.com/page/Acetyl-L-carnitine
6. Gnoni A, Longo S, Gnoni GV, Giudetti AM. "Carnitine in human muscle bioenergetics." Molecules 2020;25:182. https://pubmed.ncbi.nlm.nih.gov/31906498/
7. ConsumerLab. "Acetyl-L-Carnitine Supplements Review." https://www.consumerlab.com/reviews/acetyl-l-carnitine-supplements-review/acetyl-l-carnitine/
8. Bianchetti A, Rozzini R, Trabucchi M. "Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors." Curr Med Res Opin 2003;19:350-3. https://pubmed.ncbi.nlm.nih.gov/12841930/
9. National Research Council. Food and Nutrition Board. Recommended Dietary Allowances, 10th ed. National Academy Press, 1989.
10. Rebouche CJ. "Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism." Ann NY Acad Sci 2004;1033:30-41.
11. ConsumerLab. "Acetyl-L-Carnitine Supplements Review — ConsumerTips." https://www.consumerlab.com/reviews/acetyl-l-carnitine-supplements-review/acetyl-l-carnitine/
12. Rebouche CJ. "Carnitine." In: Ross AC, et al., eds. Modern Nutrition in Health and Disease, 11th ed. 2014:252-3.
13. Tama B, et al. "Propionyl-L-carnitine in intermittent claudication." Cureus 2021;13:e17592. https://pubmed.ncbi.nlm.nih.gov/34650861/
14. EFSA AFC Panel. "L-carnitine-L-tartrate for use in foods." EFSA J 2003.
15. Hudson S, Tabet N. "Acetyl-L-carnitine for dementia." Cochrane Database Syst Rev 2003;2003(2):CD003158. https://pubmed.ncbi.nlm.nih.gov/12804452/
16. Montgomery SA, Thal LJ, Amrein R. "Meta-analysis of ALCAR vs placebo in MCI and mild Alzheimer's." Int Clin Psychopharmacol 2003;18:61-71. https://pubmed.ncbi.nlm.nih.gov/12598816/
17. Spagnoli A, et al. "Long-term acetyl-L-carnitine treatment in Alzheimer's disease." Neurology 1991;41(11):1726-32.
18. Thal LJ, et al. "A 1-year multicenter placebo-controlled study of ALCAR in Alzheimer's disease." Neurology 1996;47(3):705-11.
19. Pennisi M, et al. "Acetyl-L-carnitine in dementia: a critical update." Nutrients 2020;12:1389. https://pubmed.ncbi.nlm.nih.gov/32408706/
20. Lodeiro M, et al. "Decreased CSF L-carnitine in early Alzheimer's disease." J Alzheimers Dis 2014;41:223-32. https://pubmed.ncbi.nlm.nih.gov/24577479/
21. Ruggenenti P, et al. "Ameliorating hypertension and insulin resistance: effects of ALCAR therapy." Hypertension 2009;54(3):567-74.
22. McMackin CJ, et al. "Alpha-lipoic acid and ALCAR on vascular function and blood pressure." J Clin Hypertens 2007;9(4):249-55.
23. Parvanova A, et al. "DIABASI trial." J Endocr Soc 2018.
24. Sayed D, et al. "ASPN guideline for painful diabetic neuropathy." J Pain Res 2024.
25. Li S, et al. "ALCAR for peripheral neuropathic pain: systematic review and meta-analysis." J Pain Res 2019.
26. Cochrane Review. "ALCAR for diabetic peripheral neuropathy." 2019.
27. Youle M, et al. "ALCAR for antiretroviral toxic neuropathy." HIV Med 2007.
28. Hershman DL, et al. "ALCAR for prevention of taxane-induced neuropathy." J Clin Oncol 2018;36(20):2048-55.
29. Loprinzi CL, et al. "ASCO guideline: chemotherapy-induced peripheral neuropathy." J Clin Oncol 2020;38(28):3325-48.
30. Veronese N, et al. "ALCAR and depressive symptoms: systematic review and meta-analysis." Psychosom Med 2018;80:154-9.
31. Leombruni P, et al. "Duloxetine vs ALCAR in fibromyalgia." Clin Exp Rheumatol 2015;33(1 Suppl 88):S82-5.
32. Vermeulen RCW, Scholte HR. "Acetyl- and propionyl-carnitine in chronic fatigue syndrome." Psychosom Med 2004;66(2):276-82.
33. DiNicolantonio JJ, et al. "L-carnitine in secondary prevention of CVD: meta-analysis." Mayo Clin Proc 2013;88:544-51. https://pubmed.ncbi.nlm.nih.gov/23597877/
34. Oyanagi E, et al. "Protective action of L-carnitine on mitochondrial function." Biochem Biophys Res Commun 2011;412:61-7.
35. Song X, et al. "L-carnitine for chronic heart failure: meta-analysis." Biomed Res Int 2017;2017:6274854. https://pubmed.ncbi.nlm.nih.gov/28497060/
36. Koeth RA, et al. "Intestinal microbiota metabolism of L-carnitine promotes atherosclerosis." Nat Med 2013;19:576-85. https://pubmed.ncbi.nlm.nih.gov/23563705/
37. Johri AM, et al. "Atherosclerosis progression with carnitine supplementation." Nutr Metab (Lond) 2022;19:26. https://pubmed.ncbi.nlm.nih.gov/35365175/
38. Tama B, et al. "Propionyl-L-carnitine for intermittent claudication." Cureus 2021;13:e17592. https://pubmed.ncbi.nlm.nih.gov/34650861/
39. Sangwung P, et al. "Mitochondrial dysfunction and insulin resistance." Endocrinology 2020;161:bqaa017. https://pubmed.ncbi.nlm.nih.gov/32060541/
40. Yazici D, Sezer H. "Insulin resistance, obesity and lipotoxicity." Adv Exp Med Biol 2017;960:277-304. https://pubmed.ncbi.nlm.nih.gov/28585204/
41. Zamani M, et al. "L-carnitine and glycemic markers: systematic review and meta-analysis." Front Nutr 2023;9:1082097. https://pubmed.ncbi.nlm.nih.gov/36698467/
42. Xu Y, et al. "L-carnitine for insulin resistance: meta-analysis." Adv Clin Exp Med 2017;26:333-8. https://pubmed.ncbi.nlm.nih.gov/28791854/
43. Vidal-Casariego A. "L-carnitine and type 2 diabetes: meta-analysis." Exp Clin Endocrinol Diabetes 2013;121:5. https://pubmed.ncbi.nlm.nih.gov/23147210/
44. Skoracka K, et al. "Diet and male (in)fertility." J Clin Med 2020;9:1400. https://pubmed.ncbi.nlm.nih.gov/32397541/
45. Agarwal A, et al. "L-carnitine in female infertility." Reprod Biol Endocrinol 2018;16:5. https://pubmed.ncbi.nlm.nih.gov/29373970/
46. Salas-Huetos A, et al. "Nutrients and sperm quality: meta-analysis." Adv Nutr 2018;9:833-48. https://pubmed.ncbi.nlm.nih.gov/30462179/
47. de Ligny W, et al. "Antioxidants for male subfertility." Cochrane Database Syst Rev 2022;5:CD007411. https://pubmed.ncbi.nlm.nih.gov/35506389/
48. Mongioi LM, et al. "Carnitine in male infertility." Andrology 2020.
49. Ismail AM, et al. "L-carnitine + clomiphene in PCOS: RCT." Eur J Obstet Gynecol Reprod Biol 2014;180:148-52. https://pubmed.ncbi.nlm.nih.gov/25015747/
50. El Sharkwy I, et al. "L-carnitine + metformin in PCOS." Gynecol Endocrinol 2019;35:701-5. https://pubmed.ncbi.nlm.nih.gov/30810434/
51. Mahdavi AM, et al. "L-carnitine in knee osteoarthritis." J Am Coll Nutr 2016;35:597-603. https://pubmed.ncbi.nlm.nih.gov/26923508/
52. Baghban F, et al. "L-carnitine in obese women with knee osteoarthritis." BMC Musculoskelet Disord 2021;22:195. https://pubmed.ncbi.nlm.nih.gov/33607984/
53. Takahashi M, et al. "L-carnitine for nocturnal leg cramps." Physiol Rep 2021.
54. Nakanishi H, et al. "L-carnitine and muscle cramps in cirrhosis." Clin Gastroenterol Hepatol 2015.
55. Miwa H. "L-carnitine for nocturnal leg cramps after stroke." Nutrition 2020.
56. Imbe A, et al. "L-carnitine for leg cramps in diabetes." Endocr J 2018.
57. Peeling P, et al. "Evidence-based supplements for athletic performance." Int J Sport Nutr Exerc Metab 2018;28:178-87. https://pubmed.ncbi.nlm.nih.gov/29345167/
58. Wall BT, et al. "L-carnitine + carbohydrate and muscle fuel metabolism." J Physiol 2011;589:963-73. https://pubmed.ncbi.nlm.nih.gov/21224234/
59. Novakova K, et al. "L-carnitine in male vegetarians." Eur J Nutr 2016;55:207-17. https://pubmed.ncbi.nlm.nih.gov/25612929/
60. Fielding R, et al. "L-carnitine in recovery after exercise." Nutrients 2018;10:349. https://pubmed.ncbi.nlm.nih.gov/29534031/
61. Mielgo-Ayuso J, et al. "L-carnitine and exercise intensity: systematic review." Nutrients 2021;13:4359. https://pubmed.ncbi.nlm.nih.gov/34959937/
62. Villani RG, et al. "L-carnitine does not promote weight loss." Int J Sport Nutr Exerc Metab 2000;10:199-207.
63. Pooyandjoo M, et al. "L-carnitine and weight loss: meta-analysis." Obes Rev 2016;17:970-6. https://pubmed.ncbi.nlm.nih.gov/27335245/
64. Derosa G, et al. "Orlistat + L-carnitine in obese diabetic patients." Endocr J 2010;57:777-86. https://pubmed.ncbi.nlm.nih.gov/20683172/
65. Derosa G, et al. "L-carnitine and lipoprotein(a) in type 2 diabetes." Clin Ther 2003;25:1429-39. https://pubmed.ncbi.nlm.nih.gov/12867218/
66. Biagiotti G, Cavallini G. "ALCAR vs tamoxifen in Peyronie's disease." BJU Int 2001;88:63-7.
67. Combination therapy studies for dry eye (ALCAR + omega-3 + CoQ10). Various clinical observations.
68. Malaguarnera M, et al. "L-carnitine reduces fatigue and improves cognition in centenarians." Am J Clin Nutr 2007;86(6):1738-44.
69. Hurot JM, et al. "L-carnitine in hemodialysis: systematic review." J Am Soc Nephrol 2002;13:708-14. https://pubmed.ncbi.nlm.nih.gov/11856775/
70. Benvenga S, et al. "L-carnitine as peripheral antagonist of thyroid hormone." Ann NY Acad Sci 2004.
71. Hug G, et al. "Serum carnitine reduction during anticonvulsant therapy." J Pediatr 1991;119:799-802.
72. Castro-Gago M, et al. "Carnitine levels in epileptic children." J Child Neurol 1998;13:546-9.
73. Verrotti A, et al. "Carnitine deficiency with valproic acid." Int J Clin Lab Res 1999;29:36-40.
74. Lheureux PE, Hantson P. "Carnitine for valproic acid toxicity." Clin Toxicol 2009;47:101-11.
75. Perrott J, et al. "L-carnitine for valproic acid overdose: systematic review." Ann Pharmacother 2010;44:1287-93.
76. Brass EP. "Pivalate-generating prodrugs and carnitine homeostasis." Pharmacol Rev 2002;54:589-98.
77. Sato K, et al. "Famotidine reduces carnitine levels through inhibition of renal carnitine transporter." Pharmazie 2025.
